Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
25.41
-0.13 (-0.51%)
At close: Nov 14, 2025, 4:00 PM EST
25.38
-0.04 (-0.14%)
Pre-market: Nov 17, 2025, 9:11 AM EST
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.48B in the quarter ending September 30, 2025, with 3.42% growth. This brings the company's revenue in the last twelve months to $16.78B, up 0.02% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.78B
Revenue Growth
+0.02%
P/S Ratio
1.73
Revenue / Employee
$455,498
Employees
36,830
Market Cap
29.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TEVA News
- 2 days ago - Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business - Seeking Alpha
- 6 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 9 days ago - AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living - GlobeNewsWire
- 11 days ago - Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Benzinga
- 12 days ago - Teva Pharmaceuticals stock surges 12% as branded drug sales outperform - Invezz
- 12 days ago - Teva Pharm third-quarter profit tops estimates as branded drugs gain - Reuters
- 12 days ago - Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS - GlobeNewsWire